Extrawell Pharmaceutical Holdings Limited (HK:0858)
:0858
0858 Stock Chart & Stats
HK$0.09
>-HK$0.01(-4.00%)
At close: 4:00 PM EST
HK$0.09
>-HK$0.01(-4.00%)
Day’s Range― - ―
52-Week RangeHK$0.04 - HK$0.15
Previous CloseN/A
Volume550.00K
Average Volume (3M)2.87M
Market Cap
HK$211.65M
Enterprise ValueHK$250.97M
Total Cash (Recent Filing)HK$994.86M
Total Debt (Recent Filing)HK$140.94M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding2,550,000,000
10 Day Avg. Volume3,479,000
30 Day Avg. Volume2,870,000
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.08
Price to Sales (P/S)1.94
P/FCF Ratio-14.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low debt-to-equity ratio (0.11) reduces financial risk and interest burden, giving management flexibility to prioritize operations, working capital, or targeted investments. Over a 2–6 month horizon this balance sheet buffer supports stability during revenue recovery and preserves borrowing capacity for strategic actions.
Positive Return On EquityA reported ROE of 16.68% indicates the company can generate shareholder returns from its existing asset base despite broader headwinds. This underlying profitability signal suggests management can leverage assets to rebuild earnings as revenues stabilize, aiding a sustainable medium-term recovery if operational cash flows improve.
Resilient Industry ExposureOperating in specialty and generic pharmaceuticals provides exposure to structurally recurring healthcare demand and prescription volumes. This durable industry backdrop supports baseline product demand and revenue opportunities over months, offering a steady market context while company-specific execution issues are addressed.
Bears Say
Declining RevenuesMaterial revenue declines (annual decrease ~7.2% and recent growth trend -11.9%) erode scale and pricing power, reducing gross margin and fixed-cost absorption. Sustained top-line weakness over several quarters will limit cash generation, reduce investment capacity, and make operational turnarounds more difficult.
Negative Cash FlowsPersistent negative operating and free cash flows mean reported profits are not converting into cash, creating liquidity strain. Over the medium term this constrains reinvestment, R&D and working capital, increases dependency on external funding, and limits the ability to execute strategic initiatives without repairing cash conversion.
Margin And Operational PressureNegative EBIT margins and a declining gross margin point to core operational inefficiencies and cost pressures. Even with a modest net margin, margin compression limits the firm's capacity to invest, absorb input cost increases, or compete on price, weakening structural competitiveness over the coming months unless margins are restored.
Extrawell Pharmaceutical Holdings Limited News
0858 FAQ
What was Extrawell Pharmaceutical Holdings Limited’s price range in the past 12 months?
Extrawell Pharmaceutical Holdings Limited lowest stock price was HK$0.04 and its highest was HK$0.15 in the past 12 months.
What is Extrawell Pharmaceutical Holdings Limited’s market cap?
Extrawell Pharmaceutical Holdings Limited’s market cap is HK$211.65M.
When is Extrawell Pharmaceutical Holdings Limited’s upcoming earnings report date?
Extrawell Pharmaceutical Holdings Limited’s upcoming earnings report date is Jun 25, 2026 which is in 79 days.
How were Extrawell Pharmaceutical Holdings Limited’s earnings last quarter?
Extrawell Pharmaceutical Holdings Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.191 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.191.
Is Extrawell Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Extrawell Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Extrawell Pharmaceutical Holdings Limited pay dividends?
Extrawell Pharmaceutical Holdings Limited does not currently pay dividends.
What is Extrawell Pharmaceutical Holdings Limited’s EPS estimate?
Extrawell Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Extrawell Pharmaceutical Holdings Limited have?
Extrawell Pharmaceutical Holdings Limited has 2,550,000,000 shares outstanding.
What happened to Extrawell Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Extrawell Pharmaceutical Holdings Limited reported an EPS of -HK$0.191 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Extrawell Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:0858
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Extrawell Pharmaceutical Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.17%
12-Months-Change
Fundamentals
Return on Equity
-30.35%
Trailing 12-Months
Asset Growth
-21.54%
Trailing 12-Months
Company Description
Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.
Technical Analysis
Qianhai Health Holdings Ltd.
―
Kontafarma China Holdings Ltd
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Huakang Biomedical Holdings Company Limited
―